Cargando…
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
BACKGROUND: Sunitinib, a receptor tyrosine kinase (RTK) inhibitor that targets multiple receptors such as vascular endothelial growth factor receptors (VEGFRs), was approved for cancer treatment in 2006. However, it was unsuccessful in treating certain cancers, particularly metastatic breast cancer...
Autores principales: | Wang, Denian, Xiao, Fei, Feng, Zhongxue, Li, Min, Kong, Lingmiao, Huang, Luping, Wei, Yong’gang, Li, Hongyu, Liu, Fei, Zhang, Haili, Zhang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526390/ https://www.ncbi.nlm.nih.gov/pubmed/32993785 http://dx.doi.org/10.1186/s13058-020-01346-y |
Ejemplares similares
-
Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade
por: Xiao, Fei, et al.
Publicado: (2021) -
Intermedin promotes vessel fusion by inducing VE‐cadherin accumulation at potential fusion sites and to achieve a dynamic balance between VE‐cadherin‐complex dissociation/reconstitution
por: Kong, Lingmiao, et al.
Publicado: (2020) -
Intermedin protects against sepsis by concurrently re-establishing the endothelial barrier and alleviating inflammatory responses
por: Xiao, Fei, et al.
Publicado: (2018) -
The “inherent vice” in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively
por: Wang, Denian, et al.
Publicado: (2017) -
Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis
por: Zhang, Haili, et al.
Publicado: (2021)